Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn’s disease stopping infliximab: when the remission state hides different types of residual disease activity
| العنوان: | Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn’s disease stopping infliximab: when the remission state hides different types of residual disease activity |
|---|---|
| المؤلفون: | Nicolas Pierre, Vân Anh Huynh-Thu, Thomas Marichal, Matthieu Allez, Yoram Bouhnik, David Laharie, Arnaud Bourreille, Jean-Frédéric Colombel, Marie-Alice Meuwis, Edouard Louis |
| المصدر: | Gut. 72:443-450 |
| بيانات النشر: | BMJ, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Gastroenterology |
| الوصف: | ObjectiveDespite being in sustained and stable remission, patients with Crohn’s disease (CD) stopping anti-tumour necrosis factor α (TNFα) show a high rate of relapse (~50% within 2 years). Characterising non-invasively the biological profiles of those patients is needed to better guide the decision of anti-TNFα withdrawal.DesignNinety-two immune-related proteins were measured by proximity extension assay in serum of patients with CD (n=102) in sustained steroid-free remission and stopping anti-TNFα (infliximab). As previously shown, a stratification based on time to clinical relapse was used to characterise the distinct biological profiles of relapsers (short-term relapsers: 6 months). Associations between protein levels and time to clinical relapse were determined by univariable Cox model.ResultsThe risk (HR) of mid/long-term clinical relapse was specifically associated with a high serum level of proteins mainly expressed in lymphocytes (LAG3, SH2B3, SIT1; HR: 2.2–4.5; pConclusionWe identified distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with CD stopping infliximab. These findings constitute an advance for the development of non-invasive biomarkers guiding the decision of anti-TNFα withdrawal. |
| تدمد: | 1468-3288 0017-5749 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be6a15be08742fffe3fa1cc21668f0a8Test https://doi.org/10.1136/gutjnl-2022-327321Test |
| رقم الانضمام: | edsair.doi.dedup.....be6a15be08742fffe3fa1cc21668f0a8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14683288 00175749 |
|---|